Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
…
13,735€
1,89%
Echtzeit-Aktienkurs Acadia Pharmaceuticals Inc.
Bid:
Ask:
Nachrichten zur Acadia Pharmaceuticals Inc. Aktie
NRx Pharmaceuticals, Inc. (NRXP) Q2 2024 Earnings Call Transcript
…
ACADIA Pharmaceuticals Inc. 2024 Q2 - Results - Earnings Call Presentation
…
Acadia Pharmaceuticals: Back In The Buy Zone
…
Acadia Pharmaceuticals: Bullish On Nuplazid And Daybue Driven Growth In CNS Treatments
…
Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
GLEN ALLEN, Va., May 15, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”),…
NRx Pharmaceuticals, Inc. (NRXP) Q1 2024 Earnings Call Transcript
…
ACADIA Pharmaceuticals Inc. (ACAD) Q1 2024 Earnings Call Transcript
…
ACADIA Pharmaceuticals Inc. 2024 Q1 - Results - Earnings Call Presentation
…
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
Amylyx Pharmaceuticals (AMLX) and Acadia Pharmaceuticals (ACAD) plunged on failure of studies.…
Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue
…
Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds
CHARLOTTESVILLE, Va., March 01, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a…
Acadia Pharmaceuticals: New Daybue Drug Already Showing Signs Of Slowing
…
Acadia Pharmaceuticals: Daybue Growth Concerns, Important Data Readout Coming
…
ACADIA Pharmaceuticals Inc. (ACAD) Q4 2023 Earnings Call Transcript
…
ACADIA Pharmaceuticals Inc. 2023 Q4 - Results - Earnings Call Presentation
…
ACADIA Pharmaceuticals Inc. Investors: Please contact the Portnoy Law Firm to recover your losses
Investors can contact the law firm at no cost to learn more about recovering their losses…
Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families
…
Adial Pharmaceuticals Receives Final Reimbursement Payment from Adovate
CHARLOTTESVILLE, Va., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”),…
BUSINESS WIRE: Nordic Pharma Group B.V. schließt über ihre Tochtergesellschaft Amring Pharmaceuticals Inc. die Übernahme von Visant Medical ab, um in den Vereinigten Staaten eine neuartige Therapie für trockene Augen einzuführen
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.BERWYN, Pennsylvania --(BUSINESS WIRE)-- 18.12.2023 --Amring Pharmaceuticals…
Acadia Pharmaceuticals: Legal Overhang On Nuplazid Removed
…
Acadia Pharmaceuticals surges 32% after win in patent suit over Nuplazid
…
ACADIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Acadia Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
ACADIA SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) and Encourages Long-Term ACAD Investors to Contact the Firm
PHILADELPHIA, Dec. 10, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Acadia Pharmaceuticals Inc.…
Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement
CHARLOTTESVILLE, Va., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”),…
ACADIA Pharmaceuticals Inc. (ACAD) Q3 2023 Earnings Call Transcript
…
Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
CHARLOTTESVILLE, Va., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (“Adial” or the “Company”), a clinical-stage…
Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
CHARLOTTESVILLE, Va., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (“Adial” or the “Company”), a clinical-stage…
Acadia Pharmaceuticals stock surges 7% on JPMorgan upgrade By Investing.com
Acadia Pharmaceuticals stock surges 7% on JPMorgan upgrade…
Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimates
Acadia (ACAD) delivered earnings and revenue surprises of 108.33% and 7.08%, respectively, for the quarter ended June 2023. Do the…
Form 8-K ACADIA PHARMACEUTICALS For: Aug 02
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Is ACADIA Pharmaceuticals (ACAD) Stock Outpacing Its Medical Peers This Year?
Here is how Acadia Pharmaceuticals (ACAD) and Abbott (ABT) have performed compared to their sector so far this year....…
Insiderhandel: CEO verkauft Aktien von ACADIA Pharmaceuticals im Wert von 3.004.350$
Davis, Stephen - Vorstand - Tag der Transaktion: 2023-07-14...…
Form 8-K ACADIA PHARMACEUTICALS For: Jul 13
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Acadia Pharmaceuticals Rights Deal and Bullish Outlook Sends Shares Surging 16%. Here’s What to Expect.
Acadia Pharmaceuticals shares surged following the announcement of the companys acquisition of expanded commercial rights for a groundbreaking drug....…
Why Acadia Pharmaceuticals Stock Is Soaring Today
Investors are cheering Acadias latest news....…
Insiderhandel: CEO verkauft Aktien von ACADIA Pharmaceuticals im Wert von 412.450$
Davis, Stephen - Vorstand - Tag der Transaktion: 2023-07-11...…
Insiderhandel: CEO verkauft Aktien von ACADIA Pharmaceuticals im Wert von 1.380.449$
Davis, Stephen - Vorstand - Tag der Transaktion: 2023-07-12...…
Acadia Pharma soars on drug rights deal, updated sales guidance
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Acadia Pharmaceuticals stock rockets 30% following expanded drug rights
Acadia Pharmaceuticals Inc. ACAD shares rallied in the extended session Thursday after the drug maker said it expanded its rights…
Insiderhandel: Principal Accounting Officer verkauft Aktien von ACADIA Pharmaceuticals im Wert von 48.300$
Kihara, James - Vorstand - Tag der Transaktion: 2023-06-15...…
Insiderhandel: Aufsichtsrat verkauft Aktien von ACADIA Pharmaceuticals im Wert von 111.906$
Brege, Laura - Aufsichtsrat - Tag der Transaktion: 2023-06-12...…
Insiderhandel: EVP, Chief Financial Officer verkauft Aktien von ACADIA Pharmaceuticals im Wert von 24.369$
Schneyer, Mark C. - Vorstand - Tag der Transaktion: 2023-06-08...…
Insiderhandel: Aufsichtsrat kauft Aktien von ACADIA Pharmaceuticals im Wert von 14.096.825$
Baker Bros. Advisors Lp - Aufsichtsrat - Tag der Transaktion: 2023-05-24...…
Insiderhandel: Aufsichtsrat kauft Aktien von ACADIA Pharmaceuticals im Wert von 5.312.457$
Baker Bros. Advisors Lp - Aufsichtsrat - Tag der Transaktion: 2023-05-23...…
Insiderhandel: Aufsichtsrat kauft Aktien von ACADIA Pharmaceuticals im Wert von 3.297.816$
Baker Bros. Advisors Lp - Aufsichtsrat - Tag der Transaktion: 2023-05-22...…
Insiderhandel: EVP, Chief Financial Officer verkauft Aktien von ACADIA Pharmaceuticals im Wert von 344.475$
Schneyer, Mark C. - Vorstand - Tag der Transaktion: 2023-05-17...…
Insiderhandel: Principal Accounting Officer verkauft Aktien von ACADIA Pharmaceuticals im Wert von 133.808$
Kihara, James - Vorstand - Tag der Transaktion: 2023-05-17...…
Insiderhandel: EVP, COO, Head of Commercial verkauft Aktien von ACADIA Pharmaceuticals im Wert von 334.553$
Teehan, Brendan - Vorstand - Tag der Transaktion: 2023-05-17...…
Acadia Pharmaceuticals (ACAD) Q1 Earnings & Sales Miss Estimates
Acadia Pharmaceuticals (ACAD) reports weaker-than-expected first-quarter 2023 results as its earnings and revenues miss the Zacks Consensus Estimate. Management maintains…